Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd (SHA:600721)
China · Delayed Price · Currency is CNY 9.26
-0.01 (-0.11%)
Feb 27, 2026, 3:00 PM CST
SHA:600721 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 391.45 | 383.47 | 366.22 | 346.37 | 278.13 | 81.15 |
Other Revenue | 2.28 | 2.28 | 3.06 | 3.51 | 3.22 | 3.38 |
| 393.73 | 385.76 | 369.28 | 349.88 | 281.35 | 84.53 | |
Revenue Growth (YoY) | -0.12% | 4.46% | 5.54% | 24.36% | 232.84% | -67.74% |
Cost of Revenue | 220.28 | 224.05 | 227.84 | 255.43 | 184.18 | 231.22 |
Gross Profit | 173.45 | 161.71 | 141.44 | 94.45 | 97.17 | -146.69 |
Selling, General & Admin | 65.55 | 68.4 | 73.72 | 78.35 | 64.51 | 64.02 |
Research & Development | 25.35 | 29.55 | 31.87 | 27.48 | 5.25 | 6.11 |
Other Operating Expenses | 5.79 | 5.22 | 5.25 | 4.79 | 4.65 | 4 |
Operating Expenses | 130.38 | 131.11 | 127.3 | 127.16 | 83.14 | 73.46 |
Operating Income | 43.07 | 30.59 | 14.14 | -32.71 | 14.04 | -220.16 |
Interest Expense | - | - | - | -0.11 | -0.05 | -0.75 |
Interest & Investment Income | 4.35 | 4.96 | 2.27 | 0.52 | 0.22 | 2.08 |
Currency Exchange Gain (Loss) | - | - | -0 | - | - | - |
Other Non Operating Income (Expenses) | 0.68 | 0.52 | -0.6 | -0.66 | -0.37 | -18.25 |
EBT Excluding Unusual Items | 48.1 | 36.07 | 15.81 | -32.97 | 13.84 | -237.08 |
Impairment of Goodwill | - | - | - | - | - | -144.15 |
Gain (Loss) on Sale of Investments | -0.13 | -0.13 | 0.7 | 0.01 | 0.44 | 5.5 |
Gain (Loss) on Sale of Assets | 0 | 0.09 | 0.01 | 0 | 0.01 | 0.56 |
Asset Writedown | -1.16 | -0.1 | -0.39 | -0.07 | -0.13 | -0.1 |
Legal Settlements | -0.38 | -0.38 | -0.11 | -0.11 | -0.3 | -0.43 |
Other Unusual Items | 2.09 | 1.3 | 0.45 | 1.02 | 48.32 | 60.03 |
Pretax Income | 48.53 | 36.86 | 16.48 | -32.12 | 62.18 | -315.68 |
Income Tax Expense | -1.67 | -4.61 | 3.51 | 2.62 | 2.3 | 4.09 |
Earnings From Continuing Operations | 50.2 | 41.48 | 12.97 | -34.74 | 59.87 | -319.76 |
Minority Interest in Earnings | - | - | - | -0.03 | -0.05 | -0 |
Net Income | 50.2 | 41.48 | 12.97 | -34.76 | 59.83 | -319.77 |
Net Income to Common | 50.2 | 41.48 | 12.97 | -34.76 | 59.83 | -319.77 |
Net Income Growth | 161.00% | 219.75% | - | - | - | - |
Shares Outstanding (Basic) | 384 | 382 | 379 | 376 | 375 | 390 |
Shares Outstanding (Diluted) | 384 | 382 | 379 | 376 | 375 | 390 |
Shares Change (YoY) | 0.46% | 0.79% | 0.92% | 0.20% | -3.79% | -2.49% |
EPS (Basic) | 0.13 | 0.11 | 0.03 | -0.09 | 0.16 | -0.82 |
EPS (Diluted) | 0.13 | 0.11 | 0.03 | -0.09 | 0.16 | -0.82 |
EPS Growth | 159.80% | 217.25% | - | - | - | - |
Free Cash Flow | 14.9 | 55.68 | 44.84 | 50.77 | 28.68 | -27.05 |
Free Cash Flow Per Share | 0.04 | 0.15 | 0.12 | 0.14 | 0.08 | -0.07 |
Gross Margin | 44.05% | 41.92% | 38.30% | 27.00% | 34.54% | -173.54% |
Operating Margin | 10.94% | 7.93% | 3.83% | -9.35% | 4.99% | -260.44% |
Profit Margin | 12.75% | 10.75% | 3.51% | -9.94% | 21.26% | -378.28% |
Free Cash Flow Margin | 3.78% | 14.44% | 12.14% | 14.51% | 10.20% | -32.00% |
EBITDA | 57.97 | 48.22 | 35.41 | -7.13 | 39.18 | -189.96 |
EBITDA Margin | 14.72% | 12.50% | 9.59% | -2.04% | 13.93% | -224.73% |
D&A For EBITDA | 14.9 | 17.63 | 21.27 | 25.58 | 25.14 | 30.19 |
EBIT | 43.07 | 30.59 | 14.14 | -32.71 | 14.04 | -220.16 |
EBIT Margin | 10.94% | 7.93% | 3.83% | -9.35% | 4.99% | -260.44% |
Effective Tax Rate | - | - | 21.29% | - | 3.70% | - |
Revenue as Reported | 393.73 | 385.76 | 369.28 | 349.88 | 281.35 | 84.53 |
Advertising Expenses | - | 0.36 | 1.09 | 0.84 | 0.4 | 0.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.